Boston Life data show Altropane aids Parkinson's diagnosis

By Elaine Rigoli

Tampa, Fla., Sept. 25 - Boston Life Sciences, Inc. said the results from its trial for the Altropan molecular imaging agent showed statistically significant superiority over the diagnosis of primary-care physicians on measures of both specificity and sensitivity, the primary endpoint of the trial.

The trial was designed to assess whether Altropane imaging is more accurate than the clinical diagnosis of primary care physicians to distinguish between tremors caused by Parkinsonian Syndrome and those associated with other disorders, as judged by comparison to a definitive diagnosis by movement disorder specialists.

The company did not release detailed results of the trial.

Based in Hopkinton, Mass., Boston Life Sciences develops diagnostic and therapeutic products for central nervous system disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.